A Phase IIa, Open-Label, Dose-Titration, Multicenter Study to Assess the Safety and Preliminary Efficacy of NI-0401 in Patients With Acute Cellular Renal Allograft Rejection.
Phase of Trial: Phase II
Latest Information Update: 29 Jun 2012
At a glance
- Drugs Foralumab (Primary)
- Indications Renal transplant rejection
- Focus Adverse reactions; Therapeutic Use
- Sponsors NovImmune SA
- 24 Mar 2012 Primary endpoint identified as (serum creatinine levels) as reported by ClinicalTrials.gov.
- 24 Mar 2012 Additional locations (Poland, United Kingdom) added as reported by European Clinical Trials Database record.
- 16 Jun 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.